NatalieTorokMDFAASLD, AGAF
Gastroenterology • Stanford, CAHepatology & Liver Transplantation
Professor
Dr. Torok is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
300 Pasteur Drive
Division Of Gastroenterology
Stanford, CA 94305Phone+1 650-498-6080- Is this information wrong?
Summary
- Our primary research interest is in liver fibrosis and matrix remodeling, and their role in the development of hepatocellular carcinoma.
Clinically, metabolic dysfunction associated steatohepatitis (MASH) is becoming the leading cause of chronic liver disease and liver cancer, and we are interested in deciphering how dynamic changes in the liver matrix accelerate this process in certain conditions such as type 2 diabetes. Of particular interest are studies on collagen architecture and connectivity and how these are implicated in mechanosensing. We are also focusing on aging-related pathways and wound healing processes. We are exploring the age-related modulation of hepatocyte stress signals, metabolic changes, and how these intersect with innate immune responses and matrix modulation in the liver. Based on these studies we have identified targets for novel small molecule inhibitors to treat fibrosis, and are performing investigator-initiated clinical trials.
As MASH is becoming the most common liver disease in the US and worldwide our ultimate goal is to target high-risk populations, and to develop novel therapeutic approaches that reverse fibrosis and improve patient outcomes.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Gastroenterology, 1999 - 2003- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1996 - 1999
Semmelweis UniversityClass of 1988
Certifications & Licensure
CA State Medical License 2003 - 2025
MN State Medical License 1999 - 2017
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2012
Clinical Trials
- The Role of Leptin Receptors in NASH Start of enrollment: 2006 Jan 01
- Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis Start of enrollment: 2021 Jul 30
- Novel MRE Technique to Assess a Risk Factor for Liver Cancer Start of enrollment: 2022 Jan 27
Roles: Principal Investigator, Contact, Sponsor-Investigator
Publications & Presentations
PubMed
- Primary sclerosing cholangitis and the path to translation.Lóránd Váncza, Natalie J Torok> ;The Journal of Clinical Investigation. 2023 Sep 1
- Shc inhibitor idebenone ameliorates liver injury and fibrosis in dietary NASH in mice.Joy X. Jiang, Alexey Tomilov, Claire Montgomery, Chun Kui Hui, Natalie J. Török, Gino A Cortopassi> ;Journal of Biochemical and Molecular Toxicology. 2021 Aug 8
- 1 citationsEditorial: Noninvasive Fibrosis Biomarkers in Patients With NASH With DiabetesWeiguo Fan, Natalie J. Török> ;Hepatology Communications. 2021 Apr 1
- Join now to see all
Press Mentions
New Screening Guidelines for Diabetes and Liver CancerFebruary 5th, 2024- Liver Cancer and t2 Diabetes: Here's Why They Are RelatedFebruary 7th, 2024
Hospital Affiliations
VA Palo Alto Heath CarePalo Alto, California
Stanford Health CarePalo Alto, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
